Tetanus Immune Globulin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tetanus Immune Globulin: From Tetanus Prophylaxis to Diabetic Cataract
One-Sentence Summary
Tetanus Immune Globulin is a human-derived passive-immunity product that neutralizes tetanus toxin. The TxGNN model predicts it may be effective for diabetic cataract, but no clinical trials and no publications currently support this direction. The prediction rests on model output alone and has no identifiable biological support.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record (the product is known as tetanus antitoxin immunoglobulin) |
| Predicted New Indication | Diabetic cataract |
| TxGNN Prediction Score | 98.61% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general knowledge, Tetanus Immune Globulin supplies pre-formed antibodies that neutralize the toxin produced by Clostridium tetani. It provides short-term passive protection and does not act on human tissue pathways.
Diabetic cataract is driven by polyol pathway activation, osmotic stress, oxidative damage and advanced glycation end products in the lens. A toxin-neutralizing antibody has no known action on any of these processes. A systemic immunoglobulin is also unlikely to reach the avascular lens at meaningful concentrations.
The high score (0.986) most likely reflects proximity within the knowledge graph rather than biological rationale. The same pattern appears in the other top predictions, which are all cataract subtypes (tetanic, craniostenosis, immature, mature, type 2 diabetes-associated, cortical, nuclear senile and senile cataract) plus diabetic retinopathy. The score is nearly identical across them, which suggests a disease-cluster effect. "Tetanic cataract" is linked to hypocalcaemia and hypoparathyroidism, not to tetanus infection, so it is likely a false positive caused by the shared word "tetanic". None of these predictions has trials or literature behind it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09656P | HyperTET S/D Injection 250 units (Grifols Therapeutics LLC) | Injection | Not listed in the licence record |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found for this product.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials or publications, and no plausible mechanism links tetanus toxin neutralization to lens pathology. The high score appears to be a graph-based artifact, so there is no basis to advance this indication.
To proceed, the following is needed:
- The package insert warnings and contraindications from HSA, which are a blocking gap for safety screening
- Mechanism of action data from DrugBank
- Any preclinical or clinical evidence that links tetanus immune globulin to lens or diabetic eye disease
- An assessment of whether a systemic or ocular route could deliver the product to the target tissue
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.